Mayo Designed Soft Tissue Ultrasound-Detectable Marker (NCT04674852) | Clinical Trial Compass
CompletedNot Applicable
Mayo Designed Soft Tissue Ultrasound-Detectable Marker
United States8 participantsStarted 2020-11-02
Plain-language summary
Researchers are trying to determine if the Mayo marker is easily seen with ultrasound making it easier, faster, and more accurate for preoperative localization of the biopsied positive lymph node.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node
* Surgical management involves preoperative radioactive seed localization of a previously identified positive axillary lymph node
* Surgery will be performed by Dr. James Jakub at Mayo Clinic Rochester, MN
* Radioactive seed localization of an axillary lymph node.
* No contraception is necessary or required.
* English speaking
Exclusion Criteria:
* Scheduled for only radioactive seed localizations in the breast (as opposed to axilla)
* Are pregnant; although the twinkling marker is made of material widely used in orthopedic procedures, and hence, has an excellent safety profile, the investigators want to exclude the population of pregnant patients in this phase 0 clinical trial.
What they're measuring
1
Ultrasound detectability
Timeframe: Time of placement to surgical resection.